Joseph brings extensive experience in complex domestic and international capital markets transactions. He navigates IPOs, including traditional and SPAC, deSPAC business combinations, follow-on offerings, and all public company filings. Joseph also leads PIPE transactions and advises companies on corporate governance matters. His client base spans various industries, including technology, biopharma, biotech, health care, insurance, funds, SaaS, CRM technology, data analytics, food and beverage, and energy.

• Assisted in the representation of Western Midstream Partners, LP (NYSE: WES), a master limited partnership formed to develop, acquire, own, and operate midstream assets, in the following transactions:
• An offering by its subsidiary, Western Midstream Operating, LP, of $800 million in aggregate principal amount of 5.45% senior notes due 2034.
• An underwritten secondary public offering of 19,000,000 common units representing limited partner interests in Western Midstream Partners by affiliates of Occidental (NYSE: OXY) for gross proceeds of approximately $679.3 million.
• Assisted in the representation of Kronos Worldwide, a leading global producer and marketer of value-added titanium dioxide pigments, and certain of its subsidiaries, in connection with the following transactions:
• An amendment to Kronos’ global revolving credit facility that increased the facility from $225 million to $300 million and extended its maturity through 2029.
• The acquisition from Venator Investments of the remaining 50% joint venture interest in Louisiana Pigment Company, L.P., not already owned by Kronos for $185 million (plus a potential earn-out of up to $15 million).
• The issuance of €75 million of Kronos’ Senior Notes due 2029.
• Assisted in supporting Old Republic International Corporation, a Chicago-based insurance holding company engaged in the business of insurance underwriting and related services, in its $400 million public offering of 5.75% senior notes due 2034.
• Assisted in counseling Nutex Health Inc. (Nasdaq: NUTX), a publicly traded health care services and operations company, in its $10 million publicly registered direct offering.